Gateway for:

Member Countries

Drug Natural Proteins

#0421


Development of Technologies for Production of Drugs on the Base of Recombinant and Natural Proteins.

Tech Area / Field

  • BIO-CGM/Cytology, Genetics and Molecular Biology/Biotechnology
  • BIO-CHM/Biochemistry/Biotechnology
  • MED-DRG/Drug Discovery/Medicine

Status
8 Project completed

Registration date
19.06.1995

Completion date
16.04.2001

Senior Project Manager
Karabashev S G

Leading Institute
Institute of Highly Pure Biopreparations, Russia, St Petersburg

Collaborators

  • Institut National de la Santé et de la Recherche Médicale / U-283, Hopital Cochen, France, Paris\nInstitut National de la Santé et de la Recherche Médicale / U-78 Complement and Information, France, Paris\nMinistère de la Défense / Research Division for Promotion of Technologies, France, Paris

Project summary

At present in the world there is much interest in the application of cytokines as a new generation of drugs. Study of the biological properties of cytokines and results of their medicobiological trials testify that cytokines may be used to obtain therapeutic preparations effective in treatment of malignant tumors, dangerous infections, septic shocks, autoimmune diseases. This explains the fact that the biggest pharmaceutical European and U.S.A. firms such as Immunex, Amgen, Biogen, Chiron, Roche, Sanofi etc. now are carrying out clinical trials of many recombinant cytokines. Interesting are also natural high-purity therapeutic preparations which act as cytokine inductors and possess well deterministic biological properties.

In Russia there are no domestic drugs to treat cytopenia induced by chemotherapy and radiation, septic shocks, toxicoses caused by chemicals, and preparations to treat radiation injuries and to protect personnel who work in nuclear power stations and are engaged in destruction of nuclear and chemical weapons.

The proposed project aims at the development of the technologies for isolation and production of genetically engineered proteins and high-purity natural compounds, and at their application as therapeutic preparations. Of genetically engineered preparations it is planned to develop the technologies for interleukins - 1 alpha and 1 -beta, -8, interleukin-1 receptor antagonist; of natural preparations - superoxide dismutase and peptidoglycane from Lbulgaricus. Medicobiological trials of these preparations are supposed to be carried out.

The project is not only process-oriented in its character. Within the project it is planned to perform enough intensive scientific research aimed to obtain new data on the properties of cytokines, which may be used to broaden applications of cytokines as therapeutic preparations.

The Institute possesses the advanced equipment necessary for the project execution.

The methodological approaches to be used in the project comply with the international requirements. The project personnel are skilled specialists who have much experience corresponding to the project tasks, which is confirmed by the results of completed research.

The project cost is U.S. $490000.

The reality of the project execution is assured by the preliminary long-term works which have shown the possibility of the production of the above preparations under laboratory conditions. The samples of these preparations have been tested in different laboratories of the world and are known. This is confirmed by the letters from authoritative French scientists. All the scientists who have supported the project visited the Institute for the past two years and can be convinced that the Institute's advanced equipment and skilled scientific personnel possessing knowledges and experience relative to modern research methods ensure the project to be executed.


Back